(3'28")

• Burmester, G.R., Álvaro-Gracia, J.M., Betteridge, N. et al. Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools. Clin Exp Rheumatol. 2020;38(6):1056-1067.
• Sundin, U., Sundlisater, N.P., Aga, A.B. et al. Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy. RMD Open. 2021;7(1):e001525. Kyburz, D., Finckh, A. The importance of early treatment for the prognosis of rheumatoid arthritis. Swiss Med Wkly. 2013;143:w13865. 
• Dumitru, R.B., Horton, S., Hodgson, R. et al. A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA). BMC Musculoskelet Disord. 2016;17:61. 
• Abdulateef, N., Gorial, F., Humadi, Y., Yasiry, D., Al Derwibee, F., Sunna, N., AlJabban, A. Clinical Outcomes of Earlier versus Delayed Treatment of Iraque Patients with Reumatoid Arthritis with Etanercept [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/clinical-outcomes-of-earlier-versus-delayed-treatment-of-iraqi-patients-with-rheumatoid-arthritis-with-etanercept/. Acessado em 10 de março de 2021.
• Curtis, J.R., Singh, J.A. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33(6):679-707.
• Smolen, J.S., Landewé, R.B.M., Bijlsma, J.W.J. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: atualizado em 2019. Ann Rheum Dis. 2020;79(6):685-699.